Drug Trial Radar · NCT04993729
Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)
Last checked: Nov 19, 2026Latest source record: Aug 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
853
Actual
Start
Jul 21, 2021
Primary completion
May 26, 2023
Study completion May 26, 2023
Sponsor
- Lead sponsor
- Tasly Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The specific aim of this double blind, randomized phase III trial is to evaluate the safety and efficacy of T89 in preventing Acute Mountain Sickness (AMS) and relieving the symptoms of AMS after rapid ascent.
Conditions
- Acute Mountain Sickness (AMS)
Interventions
T89 capsuleDrug
T89 capsule (trade name Dantonic®) is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi. T89 capsules, p.o. TID.
Placebo capsuleDrug
Placebo capsules, p.o. TID.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of baseline corrected mean LLSS score on Day 4 morning (next mornings after arrival at high altitude) between T89 and placebo groups.Time frame: Baseline and day 4
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Hypoxia Research Lab, UCSF Parnassus Campus, S-256
San Francisco, California
Affiliated Hospital of Chengdu University of TCM
Chengdu, Sichuan, China
Tibet Autonomous Region People's Hospital
Lhasa, Tibet, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.